Natera and Alliance Foundation Trials Announce Initial Translational Research Results from PALLAS Study on Molecular Residual Disease in Breast Cancer

Natera and Alliance Foundation Trials announced initial translational research results from the PALLAS study, showing that molecular residual disease (MRD) status measured by the Signatera Genome test is a highly prognostic biomarker for distant recurrence risk in stage II-III, HR+/HER2- breast cancer. The findings support Natera's strategy to integrate MRD testing into routine post-surgical risk assessment.